TinyGemsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Unique Treatment Paradigm Featured in Bell2Bell Podcast

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, was featured in the latest episode of Bell2Bell Podcast. The podcast is part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Rodney Varner, GNPX’s chairman, president and CEO, and Ryan Confer, the company’s CFO, joined the program to discuss the journeys that led them to Genprex and the promise of the company’s drug development pipeline. “As I learned more and more about the technology, it became a passion of mine, as well,” said Confer. “What we’re trying to do in cancer – using a lipid-based delivery vehicle and working with tumor suppressor genes that are naturally occurring in the body – represents a treatment paradigm that is unique and different than other options in the space, particularly chemotherapy that has such negative side effects. It is something that we believe really has the potential to change people’s lives as they’re going through such a terrible prognosis. I was excited then, and here we are 12 years later, being able to see it coming through clinical trials, seeing how safe the program has been and seeing the impact that we’re having.”

To view the full press release, visit https://ibn.fm/Kw7q9

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing treatments for patients living with cancer and diabetes. The company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company was founded in 2009 and is headquartered in Austin, Texas. For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com

TinyGems is part of the InvestorBrandNetwork.